Castle Biosciences, Inc. - Common stock (CSTL)

Competitors to Castle Biosciences, Inc. - Common stock (CSTL)

BioTheranostics, Inc.

BioTheranostics provides diagnostic tests that predict disease progression and therapeutic success in various cancers, thereby competing with Castle Biosciences in terms of providing personalized medicine solutions. Although BioTheranostics specializes in breast cancer and has carved out a niche, Castle's focus on melanoma and other skin cancers offers them a more defined target market, potentially affording them a competitive advantage in those specific areas.

DermTech, Inc. 

DermTech focuses on precision dermatology and specialized genomic testing for skin conditions, particularly skin cancer. Their non-invasive skin biopsy technology competes directly with Castle Biosciences' diagnostics, particularly in melanoma and other skin cancers. While Castle Biosciences has established a solid reputation for its genomic tests like DecisionDx, DermTech's innovative approach and emphasis on non-invasive procedures provide a competitive edge in patient comfort and sample procurement.

Guardant Health, Inc. 

Guardant Health specializes in liquid biopsy tests for cancer detection and monitoring, providing a different but complementary approach to Castle Biosciences' tissue-based genomic tests. While Castle focuses on dermal applications, Guardant's technologies appeal to a wider range of oncology specialists who might prefer less invasive testing. Guardant's advanced analytics capabilities and extensive partnerships with oncologists give it a competitive edge, especially in the rapidly growing arena of precision medicine.

Myriad Genetics, Inc. 

Myriad Genetics offers a wide range of genetic testing services, including tests for various cancers and hereditary conditions. The company’s focus on cancers, such as breast and ovarian, places it in direct competition with Castle Biosciences, which specializes in skin cancer diagnostics. Myriad's strong distribution channels and reputation built over decades give it a competitive advantage in reaching a broader oncology market.